• 提示：详情请下载说明书。

• 产品描述： VE-822 has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.

• 靶点： ATM/ATR

• 体内研究：
  80 nM VE-822单独使用增加MiaPaCa-2和PSN-1细胞停留在G1期的比率。80 nM VE-822消除MiaPaCa-2和PSN-1细胞中富含XRT的G2/M期部分。VE-822单独作用不大,而80 nM VE-822与XRT和/或gemcitabine联用则增强PSN-1细胞中的早期和晚期细胞凋亡。VE-822增加对与pChk1 Ser345阻断相关的DNA损伤剂的肿瘤应答。VE-822（80 nM）减弱ATR信号传导途径并降低肿瘤细胞对XRT和吉西他滨的应答的存活率。在正常细胞中,80 nM VE-822减弱ATR信号通路强度,但并没有增强辐射和gemcitabine杀伤正常细胞的能力

• 细胞实验： VE-822 is dissolved in DMSO and stored, and then diluted with appropriate media before use. Gemcitabine (10 nM) is added 24 h pre-XRT and is replaced with fresh medium before addition of VE-822. PSN-1 cells are treated with VE-822 (80 nM) for 1 h before, through to 18 h after, XRT (6 Gy). Apoptosis is analyzed 48 h after XRT by flow cytometry using an Annexin V-FITC kit with Pl

• 参考文献：
  1.Fokas E, et al. Cancer Treat Rev, 2013, pii: S0305-7372(13)00065-0. 2.Fokas E, et al. Cell Death Dis, 2012, 3, e441. 3.Konstantinopoulos P A , Cheng S C , Hendrickson A E W , et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial[J]. The Lancet Oncology, 2020, 21(7).

• 溶解性： DMSO:34  mg/mL  (73.3  mM)    Ethanol:<1  mg/mL

• 保存条件： 2-8℃

• 配置溶液浓度参考：
  

  	1mg	5mg	10mg
  1 mM	2.157 ml	10.786 ml	21.573 ml
  5 mM	0.431 ml	2.157 ml	4.315 ml
  10 mM	0.216 ml	1.079 ml	2.157 ml
  50 mM	0.043 ml	0.216 ml	0.431 ml

• 注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。

输入产品批号：

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *